When to intubate in GCS?

GCS ≤ 8 requires intubation for airway protection. The patient cannot protect their own airway at this level of consciousness. Motor score is the most prognostically important component.

What is the best initial fluid for sepsis resuscitation?

Lactated Ringer's (LR) is the preferred resuscitation fluid. The SMART trial (2018) showed balanced crystalloids reduced death, new renal failure, and persistent renal dysfunction compared to normal saline.

When to start vasopressors in septic shock?

Start norepinephrine (first-line vasopressor) if MAP remains < 65 mmHg after initial 30 mL/kg crystalloid resuscitation, or earlier if patient is profoundly hypotensive. Do not delay pressors to complete full fluid resuscitation.

Why can serum uric acid be normal during acute gout?

During acute inflammation, IL-6 increases renal urate excretion and redistributes urate from plasma to tissues. Up to 40% of acute gout flares have normal serum uric acid. Joint aspiration with polarized microscopy is needed for definitive diagnosis.

How do you distinguish lupus flare from infection in SLE?

Key clues: CRP is low/normal in flare but elevated in infection. Complement (C3/C4) drops in flare but is normal/elevated in infection. Procalcitonin is elevated in bacterial infection but normal in flare. Anti-dsDNA rises in flare, stable in infection.

What is the difference between DKA and HHS?

DKA features acidosis (pH 600), hyperosmolality (> 320), and minimal ketosis -typically in Type 2 DM. DKA requires insulin drip; HHS requires aggressive fluid resuscitation first.

When to give tPA in acute ischemic stroke?

IV alteplase (tPA) can be given within 4.5 hours of last known well time in eligible patients. CT head must rule out hemorrhage first. For large vessel occlusion, mechanical thrombectomy can be performed up to 24 hours with favorable imaging.

What antibiotics for community-acquired pneumonia?

Inpatient non-ICU: ceftriaxone + azithromycin. ICU: ceftriaxone + azithromycin (add vancomycin if MRSA risk). Outpatient healthy: amoxicillin. Outpatient with comorbidities: augmentin + azithromycin or respiratory fluoroquinolone. Duration: 5 days if clinically stable for 48 hours.

How to interpret iron studies?

Iron deficiency: low ferritin (< 30), high TIBC, low iron, low transferrin saturation (< 20%). Anemia of chronic disease: normal/high ferritin (acute phase reactant), low TIBC, low iron. A ferritin of 50-100 in an inflamed patient may still represent iron deficiency.

What is the correction rate for hyponatremia?

Correct sodium no more than 8 mEq/L in 24 hours to avoid osmotic demyelination syndrome (ODS). For symptomatic severe hyponatremia with seizures, give 3% hypertonic saline 100-150 mL bolus over 10-20 minutes. If overcorrected, use D5W + DDAVP rescue protocol.

When to start antibiotics in meningitis?

Within 30-60 minutes. Do NOT delay antibiotics for LP or CT. Draw blood cultures, start empiric antibiotics (vancomycin + ceftriaxone ± ampicillin if > 50 or immunocompromised), then perform LP when possible. Dexamethasone should be given before or with the first antibiotic dose.

DOACs vs warfarin in antiphospholipid syndrome?

DOACs are contraindicated in APS. The TRAPS trial (2018) showed rivaroxaban was inferior to warfarin with more thrombotic events in triple-positive APS patients. Warfarin with INR target 2-3 is the standard for APS, indefinitely.

How to manage scleroderma renal crisis?

ACE inhibitors (captopril) are life-saving -start immediately and titrate aggressively. Do NOT hold for rising creatinine. Steroids > 15 mg prednisone per day precipitate scleroderma renal crisis. ARBs are NOT a substitute -evidence is only for ACEi.

What are the 4 pillars of heart failure treatment?

Guideline-directed medical therapy (GDMT) for HFrEF: (1) ARNI or ACEi/ARB, (2) beta-blocker (carvedilol, metoprolol succinate, or bisoprolol), (3) MRA (spironolactone or eplerenone), (4) SGLT2 inhibitor (dapagliflozin or empagliflozin). All four should be initiated and titrated to target doses.

RoundsRx

Dashboard

Overview

Recent

Rotations

Quick Reference

Antibiotic Guide Analgesia Guide Sedation Guide Bowel Regimen Electrolyte Replacement Pain Management & Conversions Drug Interactions Anticoag Reversal IV Fluid Guide Inotropes Guide Vasopressors Insulin Guide Code Blue & Rapid Response Procedures Guide ECG Interpretation Lab Interpretation Radiology Quick Ref GCS Pocket Card Admission Orders & I-PASS Landmark Trials

Tools

💎 Clinical Pearls 🧠 Pimp Me Quiz 🧮 Clinical Calculators 📰 What's New 🎓 Intern Survival Guide ✅ Rounding Checklists 🩺 Procedure Guides ⚡ Electrolyte Replacement 💧 IV Fluids Guide 🩸 Transfusion Guide 💓 ECG Pattern Guide 🧪 Lab Interpretation Guide 📱 QR Poster 🔗 Resources 🎙️ Channels & Podcasts 🎮 Medical Games 🏛️ Famous Cases 🎬 Media Library

ℹ️ About

Available offline

EmergentICUCardiology

Acute Decompensated Heart Failure

Acute worsening of HF symptoms requiring urgent intervention. Classify the hemodynamic profile first (Warm/Cold × Wet/Dry) -it drives everything. For chronic HF and GDMT optimization, see Heart Failure (Chronic).

🔍 Overview

Hemodynamic Profiles (Stevenson / Forrester)

Classify your patient before reaching for diuretics. The profile drives the entire management strategy.

Profile	Perfusion	Congestion	Management
Warm & Wet (~70%)	Adequate (warm extremities, normal mentation)	Yes (JVD, edema, crackles)	IV diuresis. This is the most common profile. Furosemide, monitor UOP, daily weights.
Cold & Wet (~20%)	Impaired (cold, clammy, AMS, low UOP)	Yes	ICU. Inotropes (dobutamine/milrinone) + diuresis. May need invasive monitoring. Consider mechanical circulatory support (MCS) early.
Cold & Dry (~5%)	Impaired	No	Cardiogenic shock. Pressors + inotropes + MCS. See Cardiogenic Shock topic.
Warm & Dry (~5%)	Adequate	No	Compensated. Optimize oral GDMT. Do NOT over-diurese. Symptom management.

Presentation & Workup

Symptoms

Dyspnea, orthopnea, paroxysmal nocturnal dyspnea
Rapid weight gain (> 2 kg in 48 hrs)
Leg edema, fatigue, decreased exercise tolerance

Exam

JVD, S3 gallop, pulmonary crackles, pitting edema
Elevated JVP = elevated filling pressures (wet)
Cool extremities, narrow pulse pressure = low output (cold)

Initial Labs & Imaging

Test	Why
BNP / NT-proBNP	Most sensitive. Very high NPV for ruling out HF. BNP > 400 or NT-proBNP > 900 supports ADHF.
CXR	Pulmonary vascular congestion, Kerley B lines, cardiomegaly, pleural effusions. Fastest imaging.
Echo	Definitive. EF (HFrEF vs HFpEF), wall motion abnormalities, valvular disease, pericardial effusion.
BMP	Cr (tracks with diuresis), Na⁺ (hyponatremia = poor prognosis), K⁺, bicarb.
Troponin	Rule out ACS as trigger. Demand ischemia common in ADHF.
ECG	STEMI trigger? Afib with RVR? New LBBB?
CBC, LFTs, TSH	Anemia worsens HF. Congestive hepatopathy. Thyroid disease is reversible cause.

Common Triggers -What Tipped Them Over?

Medication non-adherence -most common, especially diuretics and sodium restriction
Dietary indiscretion -sodium/fluid overload
ACS / ischemia -always rule out with troponin + ECG
Afib with RVR -loss of atrial kick + tachycardia-mediated worsening
Uncontrolled HTN -flash pulmonary edema
Infection / sepsis -increased metabolic demand on failing heart
Worsening renal function -impaired diuresis
Anemia, thyroid disease, PE, medication changes (NSAIDs, CCBs, TZDs)

🚨 Management

Decongestion Strategy (Warm & Wet)

Step 1 -IV Diuresis

IV furosemide -start at 1–2.5× the home oral dose IV. If diuretic-naive, start 40 mg IV. Monitor UOP every hour -target 0.5–1 mL/kg/hr. UOP < 200 mL in 2 hrs = inadequate response.

Step 2 -Diuretic Resistance

Double the furosemide dose OR add metolazone 2.5–5 mg PO 30 min before furosemide (sequential nephron blockade) DOSE, 2011. Or switch to continuous furosemide infusion (10–40 mg/hr). Acetazolamide 500 mg IV daily as adjunct to loop diuretics improves decongestion ADVOR, 2022. Monitor K⁺ and Mg closely -replace aggressively.

Step 3 -Vasodilators (if hypertensive)

Nitroglycerin drip 5–200 mcg/min -reduces preload, improves dyspnea rapidly. Ideal for flash pulmonary edema with SBP > 140. Or nitroprusside 0.3–5 mcg/kg/min (afterload + preload reduction) -requires arterial line, cyanide toxicity risk > 48h. Avoid vasodilators if SBP < 90.

Step 4 -Respiratory Support

BiPAP/CPAP for acute pulmonary edema -reduces work of breathing, ↓ preload, ↓ afterload, buys time for diuretics to work. 3CPO, 2008: NIV reduced dyspnea and physiologic distress but no mortality benefit vs standard O₂. Intubate if: worsening hypoxia despite NIV, RR > 35, inability to protect airway, hemodynamic collapse.

Monitoring

Daily weights (gold standard for tracking decongestion). Daily BMP. UOP q1h (Foley recommended). Cr bump ≤ 0.3 mg/dL acceptable ("acceptable cardiorenal syndrome"). Net negative 1–2 L/day is a reasonable target.

Transition to Oral

When clinically euvolemic: JVD resolved, crackles gone, comfortable on exertion, at dry weight. Convert to oral furosemide at 2× IV dose. Reassess at 24 hrs before discharge.

Cold & Wet / Low Output -DO NOT give aggressive diuretics alone. These patients need inotropic support (dobutamine or milrinone) before or alongside diuresis. ICU admission. Consider MCS early if deteriorating. See Cardiogenic Shock topic.

💊 ADHF Medications

Acute Agents

Drug (Brand)	Dose	Role	Key Notes
Furosemide (Lasix) 1ST LINE	40–200 mg IV bolus or 10–40 mg/hr infusion	First-line diuretic. Decongestion.	1–2.5× home oral dose IV. Monitor UOP, K⁺, Mg, Cr daily. Continuous infusion may cause less ototoxicity than large boluses.
Bumetanide (Bumex) ALTERNATIVE	1–4 mg IV	Alternative loop diuretic. 40:1 ratio (furosemide 40 mg ≈ bumetanide 1 mg).	More predictable oral bioavailability than furosemide. Some prefer in outpatient setting.
Metolazone (Zaroxolyn) ADD-ON	2.5–10 mg PO 30-60 min before loop diuretic	Sequential nephron blockade. Overcomes diuretic resistance.	Thiazide-like. Works even at low GFR (unlike HCTZ). Massive electrolyte shifts -monitor K⁺, Mg, Na aggressively.
Chlorothiazide (Diuril) ADD-ON (IV)	500–1000 mg IV 30 min before loop diuretic	IV thiazide for sequential nephron blockade. Use when NPO or fast onset needed.	Only IV thiazide in US. Onset 15 min, duration 6–12h. Fails below eGFR 30 (unlike metolazone). Expensive (~$40–80 per dose). Severe hypokalemia, hyponatremia -monitor K⁺, Mg, Na aggressively. Dose BEFORE the loop, never after.
Acetazolamide (Diamox) ADD-ON	500 mg IV daily × 3 days	Proximal tubule block (carbonic anhydrase inhibitor). Add-on for diuretic resistance and when metabolic alkalosis develops from loop diuresis.	ADVOR, 2022: successful decongestion at day 3 42% vs 30% (12% absolute increase, NNT < 9; RR 1.46) when added to loop. Works upstream of the loop so it stacks with thiazide (different site). Watch for metabolic acidosis (expected from mechanism) and hypokalemia. Dose-reduce at low eGFR.
Tolvaptan (Samsca) AQUARETIC / NICHE	15–30 mg PO daily (inpatient start only)	V2 receptor antagonist (aquaretic). Excretes free water only, no Na effect. For hypervolemic hyponatremia (Na < 125) when further diuresis would worsen sodium.	EVEREST, 2007: symptom and weight benefit, no mortality benefit. Must start inpatient -rapid Na correction risk (ODS). Avoid in cirrhosis (hepatotoxicity). Short-term bridge only.
Nitroglycerin (Tridil) HYPERTENSIVE ADHF	5–200 mcg/min IV drip	Preload reduction. Rapid relief of dyspnea in flash pulmonary edema with SBP > 140.	Venodilator predominantly. Titrate to symptom relief. Avoid if SBP < 90, severe AS, RV infarct, or PDE5 inhibitor use (sildenafil within 24h).
Nitroprusside (Nipride) SPECIALIZED	0.3–5 mcg/kg/min IV	Afterload + preload reduction. Refractory hypertensive ADHF.	Requires arterial line. Cyanide toxicity risk > 48h or > 2 mcg/kg/min. Thiocyanate levels if prolonged. Avoid in renal failure (thiocyanate accumulation).
Dobutamine (Dobutrex) COLD & WET	2–20 mcg/kg/min IV	Inotrope for low-output state. Cold & Wet profile.	↑ CO, ↑ HR. Never use alone if MAP < 65 -pair with NE. Tachyphylaxis after 72h. See Inotropes Guide.
Milrinone (Primacor) COLD & WET / RV	0.125–0.75 mcg/kg/min IV (skip loading dose)	Inodilator. RV failure, pulmonary HTN, patients on chronic BB.	↓ PVR (key advantage in RV failure). Renally cleared -dose-adjust in AKI. Longer half-life (2–3h) than dobutamine's ~2 min.
Norepinephrine (Levophed) 1ST LINE PRESSOR	0.05–1 mcg/kg/min IV (titrate to MAP ≥ 65)	First-line vasopressor for hypotension or cardiogenic shock complicating ADHF. Pair with dobutamine or milrinone if low CO.	SOAP II, 2010: preferred over dopamine (fewer arrhythmias, better cardiogenic shock outcomes). Central line preferred (extravasation necrosis risk peripherally). Once pressors needed, hold ACEi/ARB/ARNI, BB, MRA, SGLT2i until off pressors.
Ferric carboxymaltose (Injectafer) INPATIENT IRON	15 mg/kg IV (max 750 mg/dose) × 2 doses separated by ≥ 7 days	Iron repletion in iron-deficient HF. Give during admission, not outpatient, for maximum event reduction.	AFFIRM-AHF, 2020: 26% reduction in HF hospitalizations at 52 weeks. Criteria: ferritin < 100 OR ferritin 100–299 + TSAT < 20%. Screen every ADHF admission. Avoid in active infection. Rare anaphylaxis (safer than older iron dextran).

GDMT in ADHF -What to Do

Do not stop GDMT abruptly during ADHF hospitalization. Continue at reduced doses if needed. The exception: frank cardiogenic shock → hold everything until stabilized.

Drug Class	During ADHF	When to Hold
ACEi / ARB / ARNI* *ARNI = Angiotensin Receptor-Neprilysin Inhibitor (sacubitril-valsartan)	Continue unless hypotensive or AKI	SBP < 90, Cr rising > 30%, K⁺ > 5.5
Beta-blocker	Reduce dose if decompensated. Do NOT stop abruptly.	Cardiogenic shock, symptomatic bradycardia, severe hypotension
MRA* (spironolactone) *MRA = Mineralocorticoid Receptor Antagonist (spironolactone, eplerenone)	Continue if K⁺ stable	K⁺ > 5.0, AKI
SGLT2i* *SGLT2i = Sodium-Glucose Co-Transporter 2 Inhibitor (dapagliflozin, empagliflozin)	Continue if tolerated. EMPULSE, 2022: empagliflozin started in-hospital ADHF → clinical benefit.	eGFR < 20, DKA risk

Cardiogenic shock exception: the ONLY scenario to hold GDMT entirely.

In Cold & Wet or Cold & Dry profiles with hypotension requiring pressors:

HOLD: ACEi / ARB / ARNI, beta-blocker, MRA, SGLT2i, nitrates, hydralazine
START: norepinephrine for MAP, plus dobutamine for low CO (milrinone preferred if RV failure or pulmonary HTN)
CONTINUE (at adjusted dose): loop diuretic, titrated to UOP and MAP. Decongestion is still needed, just carefully.
Resume sequentially once off pressors, MAP stable > 65, and Cr not rising: ACEi/ARB first, then beta-blocker, then MRA, then SGLT2i. Titrate back to home doses before discharge.

Outside of frank cardiogenic shock, reduce, don't stop. B-CONVINCED 2009 established continuing beta-blockers through ADHF was safer than stopping them. Abrupt BB withdrawal causes rebound tachycardia and ischemia.

Meds to Come OFF at Admission

These aren't GDMT, but they drive or perpetuate HF. Review the full med list on admission and deprescribe aggressively. Missing these is a common rounding oversight.

Drug Class	Why it comes off	Notes
NSAIDs STOP	Prostaglandin inhibition blunts loop diuretic response, drives AKI, increases HF hospitalizations.	Includes ibuprofen, naproxen, ketorolac, diclofenac, and COX-2 inhibitors (celecoxib). Use acetaminophen or adjuvants for pain.
Non-DHP CCBs (diltiazem, verapamil) STOP in HFrEF	Negative inotropy worsens HF exacerbation. Contraindicated in HFrEF.	Amlodipine and felodipine are the only CCBs considered safe in HFrEF. Non-DHPs are OK in HFpEF when rate control is needed.
Thiazolidinediones (pioglitazone, rosiglitazone) STOP	PPAR-γ activation drives Na and water retention. Increased HF hospitalization; contraindicated in NYHA III-IV.	Switch diabetes management to SGLT2i or GLP-1 RA (both reduce HF events).
Saxagliptin HOLD / SWITCH	SAVOR-TIMI 53 showed an increased HF hospitalization signal. Sitagliptin and linagliptin appear safer.	Switch to sitagliptin, or better, to SGLT2i or GLP-1 RA.
Pregabalin / gabapentin HOLD	Peripheral edema is common and can mimic or worsen HF volume overload.	Especially hold if edema is disproportionate to the congestion picture. Consider duloxetine or TCA for neuropathic pain.
High-dose glucocorticoids MINIMIZE	Mineralocorticoid activity at high doses drives Na and water retention, HTN.	Not always possible to stop (autoimmune disease). Use lowest effective dose. Hydrocortisone has less mineralocorticoid effect at replacement doses.
Anti-arrhythmics with negative inotropy (flecainide, propafenone, disopyramide) AVOID in HFrEF	Class IC agents increase mortality in structural heart disease (CAST). Disopyramide is negatively inotropic.	Amiodarone and dofetilide are the only rhythm-control agents considered safe in HFrEF.
Excess IV fluids STOP	Overzealous maintenance fluids or high-Na medication carriers undo diuresis. Reconcile total Na and volume intake daily.	Convert IV meds to concentrated formulations. Use D5W as carrier when a drip is essential.

For full chronic GDMT optimization (the four pillars, titration targets, key trials), see Heart Failure (Chronic).

🪜 Diuretic Escalation Ladder

The Ladder, Step by Step

Most "diuretic resistance" is actually under-dosed loop OR an unaddressed reversible cause. Work through this order; don't skip rungs.

Step 0: Address reversible causes first. Stop NSAIDs (prostaglandin inhibition blunts loop response). Treat hypotension (kidneys can't diurese if MAP is too low, may need pressors to perfuse them). Switch PO to IV when gut edema is present. Check TSH (hypothyroid fluid retention mimics resistance). Consider bilateral renal artery stenosis if ACE-induced AKI pattern.
Step 1: Max the loop. Double the IV dose (up to 200 mg furosemide IV bolus), switch from PO to IV, or start a continuous infusion (10-40 mg/hr). Gut edema makes PO absorption unreliable, so IV is the default in ADHF.
Step 2: Add a tubular co-blocker (sequential nephron blockade). Two options at different tubular sites that can be used alone or stacked: thiazide (metolazone PO or Diuril IV) blocks the distal tubule, and acetazolamide 500 mg IV daily × 3 blocks the proximal tubule. ADVOR 2022: acetazolamide added to loop produced successful decongestion in 42% vs 30% at day 3 (12% absolute increase, NNT < 9; RR 1.46). Acetazolamide is particularly useful when loop diuresis has caused metabolic alkalosis. Give the thiazide 30-60 min before the loop.
Step 3: Start an SGLT2 inhibitor if not already on one. Dapagliflozin 10 mg PO or empagliflozin 10 mg PO. EMPULSE / EMPAG-HF 2022: in-hospital start during ADHF reduced weight, NT-proBNP, and clinical events. Also foundational GDMT with mortality benefit. Drop the loop dose ~25% when starting to avoid over-diuresis.
Step 4: Albumin + furosemide sandwich if serum albumin < 2.5 g/dL. See full breakdown at the bottom of this section.
Step 5: Tolvaptan if hypervolemic AND hyponatremic (Na < 125). Blocks ADH at the collecting duct so the kidney excretes free water only, no Na effect. Must start inpatient (rapid-correction risk). Avoid in liver disease. EVEREST 2007 showed symptom and weight benefit without mortality benefit.
Step 6: Ultrafiltration or dialysis if all pharmacologic options fail and the patient remains volume-overloaded with AKI or refractory acidosis.

Furosemide vs Diuril vs Metolazone

Feature	Furosemide (Lasix)	Chlorothiazide (Diuril)	Metolazone (Zaroxolyn)
Class	Loop	Thiazide (IV only in US)	Thiazide-like (PO only)
Role	Primary diuretic	Add-on for resistance	Add-on for resistance
Site of action	Thick ascending limb (NKCC2)	Distal tubule (NCC)	Distal tubule (NCC)
Route	IV or PO	IV only	PO only
Typical dose	20-200+ mg IV	500-1000 mg IV	2.5-10 mg PO
Onset	IV 5 min / PO 30 min	IV 15 min	PO 60 min
Duration	~2 h	6-12 h	12-24 h (longest)
% filtered Na blocked (alone)	~25% (most potent single agent)	~3-5%	~5%
Works at eGFR < 30?	Yes	No	Yes (unique among thiazides)
Cost per dose	Pennies	~$40-80	Pennies
Main toxicities	Hypokalemia, hypomagnesemia, ototoxicity (high dose / rapid push), pre-renal AKI	Severe hypokalemia, hyponatremia, hypomagnesemia	Same as Diuril but longer and more profound (24h action window)
One-liner	The engine	Fast IV turbo	Long-acting PO turbo

Which Thiazide When?

Patient can swallow, any eGFR: metolazone 2.5-10 mg PO 30-60 min before the loop. Default choice. Cheap, long-acting, works in advanced CKD.
NPO, or need fast predictable onset: Diuril 500-1000 mg IV 30 min before the loop. Works in 15 min. Expensive. Fails below eGFR 30.
eGFR < 30: metolazone is the only option. Diuril and HCTZ lose efficacy at this level of renal function.

Two common mistakes:

Reaching for Diuril when metolazone PO would work. Diuril is expensive ($40-80 per dose vs pennies for metolazone) and shorter-acting. If the patient can swallow and isn't in fulminant gut edema, metolazone is the default.
Giving the thiazide after or with the loop. The synergy depends on the thiazide being at the distal tubule BEFORE the loop dumps Na downstream. Dose the thiazide 30-60 min first, every time.

Key Adjuncts (Beyond Loop + Thiazide)

Drug	Dose	Mechanism	When to reach for it
Acetazolamide (Diamox) ADVOR 2022	500 mg IV daily × 3 days	Proximal tubule carbonic anhydrase inhibitor. Blocks Na/HCO₃ reabsorption upstream of the loop.	Added to loop in ADHF → 46% more successful decongestion at day 3. Especially useful when loop diuresis has caused metabolic alkalosis. Can stack with thiazide (different site).
Dapagliflozin / Empagliflozin GDMT + DIURESIS	Dapa 10 mg PO / Empa 10 mg PO daily	Proximal tubule SGLT2 block. Modest natriuresis plus mortality/HF-hospitalization benefit independent of diabetes.	Start in-hospital during ADHF if not already on one. EMPULSE / EMPAG-HF 2022 showed reduced weight, NT-proBNP, clinical events. Drop loop ~25% to avoid over-diuresis.
Tolvaptan (Samsca) NICHE	15-30 mg PO daily (inpatient start only)	V2 receptor antagonist (aquaretic). Blocks ADH at collecting duct. Excretes free water only, no Na effect.	Hypervolemic AND hyponatremic (Na < 125) when further diuresis would worsen sodium. Liver toxicity limits long-term use. Avoid in cirrhosis.
Hypertonic saline + high-dose furosemide NICHE / EU	3% saline 150 mL + furosemide 250-500 mg IV, BID	Tonicity gradient mobilizes interstitial Na back into the vascular space, so the loop has more Na to excrete.	Refractory HF failing standard escalation. More European than US practice. SMAC-HF 2011. Avoid if Na > 140.

Step 0 checklist: reversible causes of "diuretic resistance" to rule out FIRST

NSAIDs (including ketorolac), prostaglandin inhibition blunts loop response. Stop them.
Hypotension, kidneys can't diurese below a perfusion threshold. MAP < 65 may need pressor support before more diuretic.
Gut edema, PO furosemide bioavailability drops dramatically. Switch to IV.
Hypothyroidism, fluid retention mimics volume overload. Check TSH.
Bilateral renal artery stenosis, ACE-induced AKI looks like diuretic resistance. Consider if Cr jumps on ACEi/ARB with diuretic.
Non-adherence to sodium restriction, ask the family what the patient is actually eating.
Hypoalbuminemia < 2.5, impairs loop delivery to its tubular target (see sandwich, Step 4).

What NOT to do (classic traps):

"Renal-dose dopamine" (1-3 mcg/kg/min), no benefit. ROSE-HF 2013 was the definitive nail in the coffin. Don't order it.
Nesiritide (recombinant BNP), ASCEND-HF 2011 neutral on outcomes, increases hypotension. Abandoned in most centers.
Aggressive fluid restriction in cardiogenic shock, the kidneys need perfusion pressure. Restricting fluid here worsens AKI without improving congestion.

Albumin + Furosemide "Sandwich" (Step 4 of the Ladder)

For diuretic-resistant edema in hypoalbuminemic patients. Two mechanisms combined:

Oncotic pull. Albumin raises plasma oncotic pressure, mobilizing interstitial fluid back into the vascular space so the loop has volume to diurese.
Drug delivery. Furosemide is ~95% albumin-bound. In hypoalbuminemia, less drug reaches the proximal tubule for active secretion, so less reaches its NKCC2 target. Supplementing albumin restores drug delivery to the thick ascending limb.

When to use (BOTH required):

Diuretic-resistant edema despite max loop + thiazide
Serum albumin < 2.5 g/dL

Classic settings:

Nephrotic syndrome with anasarca
Cirrhotic refractory edema
ICU third-spacing / capillary leak
Post-op volume overload with low albumin

Dosing:

Albumin 25% 100 mL IV (25 g) over 30 min
Then furosemide 40-80 mg IV push at the end of the infusion
Repeat q6-12h if needed

Don't use if albumin is normal. Expensive placebo with no benefit. Effect is transient (hours), so it's a bridge, not a fix. Watch for flash pulmonary edema if the heart can't handle the mobilized volume.

📋 On Rounds

On Rounds

Pimp Questions

What is cardiorenal syndrome and when should you stop diuresing?

Worsening renal function during HF treatment. A Cr bump of ≤ 0.3 mg/dL is acceptable and does not indicate stopping diuresis. It's often from reduced renal perfusion pressure -continue if congestion persists. Stop or slow if Cr rising > 0.5 or K⁺ becoming dangerous.

Why should beta-blockers NOT be started in acute decompensation?

Starting beta-blockers in a decompensated state (where cardiac output is already low) can precipitate cardiogenic shock. Wait until the patient is euvolemic and stable. However, do NOT stop them if already on them -abrupt discontinuation worsens outcomes.

What are the 4 pillars of GDMT for HFrEF and why must you start all four?

(1) ARNI (sacubitril-valsartan) or ACEi/ARB, (2) Evidence-based beta-blocker (carvedilol, metoprolol succinate, bisoprolol -NOT atenolol/metoprolol tartrate), (3) MRA (spironolactone or eplerenone), (4) SGLT2 inhibitor (dapagliflozin or empagliflozin). Each independently reduces mortality by 15-30%. Combined, they reduce mortality ~70% vs placebo. Start all four early -don't wait to titrate one before starting the next.

How do you know if your diuretic dose is working in ADHF, and when should you escalate?

Track net fluid balance, daily weights, and urine output -not BNP. Good diuretic response: UOP 100-150 mL/hr in first 2h after IV furosemide, net negative 1-2L/day, weight loss 0.5-1 kg/day. If inadequate response (UOP < 100 mL in 2h): double the IV dose (ceiling effect -need higher dose to reach threshold in Loop of Henle). If still inadequate → add metolazone 5 mg PO 30 min before furosemide (sequential nephron blockade).

Clinical Examples

📋 Case 1, Warm and Wet with Diuretic Resistance

Patient: 68 y/o M with HFrEF (EF 25%), presenting with 10-lb weight gain, orthopnea, and bilateral leg edema. Home furosemide 80 mg PO BID.

Key findings: JVP 14 cm, bibasilar crackles, 3+ pitting edema. BNP 3,200, Cr 1.6 (baseline 1.2), K⁺ 3.2.

Management:

IV furosemide 160 mg bolus (2x home oral dose), monitor UOP, target > 200 mL in 2h
UOP 80 mL in 2h, double to 320 mg IV, add metolazone 5 mg PO 30 min prior
Continue GDMT: SGLT2i safe in-hospital EMPULSE, 2022
Replete K⁺ aggressively (target > 4.0), daily weights and strict I/Os

Teaching point: Diuretic resistance requires dose escalation (ceiling effect), then sequential nephron blockade with metolazone. A Cr bump ≤ 0.3 is acceptable during active diuresis.

📋 Case 2, Cold and Wet Requiring Inotropes

Patient: 72 y/o F with HFrEF (EF 15%), presents with confusion, cool mottled extremities, and anasarca. SBP 78.

Key findings: MAP 52, narrow pulse pressure, lactate 4.1, Cr 3.2 (baseline 1.4), BNP 8,400. Echo: EF 12%.

Management:

ICU admission, cold and wet profile (low CO + congestion)
Start dobutamine 5 mcg/kg/min to improve cardiac output before diuresis
Once MAP improves, add IV furosemide for decongestion
Reduce BB dose but do NOT discontinue abruptly

Teaching point: Cold and wet is the most dangerous profile. These patients need inotropes before diuresis, you cannot diurese a heart that is not generating adequate forward flow.

📋 Case 3, New-Onset HFrEF with AF Trigger

Patient: 58 y/o M, no cardiac history, 1 week of progressive dyspnea with new AF and RVR (HR 152).

Key findings: JVP 12 cm, S3 gallop, BNP 2,800. Echo: EF 30%, dilated LV, moderate MR.

Management:

Rate control with IV amiodarone (avoid diltiazem in HFrEF, negative inotrope)
IV furosemide 40 mg (diuretic-naive starting dose)
Initiate all 4 GDMT pillars: ARNI + BB + MRA + SGLT2i PARADIGM-HF, 2014
Anticoagulation for AF, coronary angiogram to rule out ischemic etiology

Teaching point: Tachycardia-mediated cardiomyopathy from uncontrolled AF is reversible with rate/rhythm control. Start all 4 GDMT pillars early, do not wait to titrate one before starting the next.

📋 Sample Presentation

"Mr. Davis is a 74-year-old with HFrEF (EF 30%) presenting with 5 days of worsening dyspnea, 8-pound weight gain, and 3-pillow orthopnea. He was started on his home furosemide 80 mg daily last week but ran out. His BNP is 2,400, creatinine is 1.4 from baseline 1.1, and CXR shows pulmonary edema. He is warm and wet -he received IV furosemide 80 mg with 1,400 mL of UOP in the first 6 hours. He's on day 2, down 2.6 kg from admission weight, creatinine 1.5, K⁺ 3.4 for which we're repleting. GDMT is continued. Plan is to transition to oral diuresis today and target discharge tomorrow if he remains comfortable."

📋 Case 4, New HFrEF: Rapid GDMT Initiation (STRONG-HF)

Patient: 58M with newly diagnosed HFrEF (EF 25%), BP 118/72, HR 78, K⁺ 4.2, Cr 1.1. Currently on no cardiac medications.

🔄 Old approach: Start ACEi → wait weeks → add BB → wait weeks → add MRA → months later maybe ARNI. Patients spent months without full therapy.

New approach (2022 AHA/ACC, STRONG-HF, 2022): Start all 4 pillars within 1–2 weeks at low doses. Don't wait for one to reach target before starting the next.

Timepoint	Action
Day 1 (Admission)	SGLT2i: Dapagliflozin (Farxiga) 10mg daily -start immediately, no titration needed, minimal BP effect. Easiest pillar to add on day 1.
Day 2–3	ARNI: Sacubitril-valsartan (Entresto) 24/26mg BID -if SBP > 100 and off pressors. Go straight to ARNI (skip ACEi if new diagnosis). If already on ACEi, must wash out 36h before starting ARNI. Check BMP: K⁺ and Cr before adding MRA.
Day 3–5 (once near-euvolemic, off pressors)	Beta-blocker: Carvedilol (Coreg) 3.125mg BID -start low. Do NOT start during active decompensation or on inotropes (risk of cardiogenic shock). Wait until diuresis has taken effect and hemodynamics are stable. MRA: Spironolactone (Aldactone) 25mg daily -if K⁺ < 5.0 and eGFR > 30.
All 4 pillars on board within 1 week. Now uptitrate in parallel:
Week 2	Entresto → 49/51mg BID, carvedilol → 6.25mg BID (if BP and HR tolerate).
Week 4	Entresto → 97/103mg BID (target dose), carvedilol → 12.5mg BID.
Week 8	Carvedilol → 25mg BID (target dose).

Key principles:

Each drug reduces mortality independently -every day without full GDMT is a missed opportunity.
Hypotension (SBP < 90) is the main limiting factor -prioritize ARNI > BB > MRA if BP-limited.
"Creatinine bumps" of 0.3–0.5 are acceptable when starting RAAS inhibitors -don't reflexively stop.
SGLT2i + MRA together are safe -monitor K⁺ but the risk of hyperkalemia is lower than feared.

📋 Case 5, Warm & Wet Decompensation (Known HFrEF)

Patient: 64F with known HFrEF (EF 20%), presents with orthopnea, PND, bilateral crackles, JVP 14cm, 2+ pitting edema. BP 142/88, SpO₂ 90% on RA.

Profile: Wet & Warm (congested, adequate perfusion) -most common presentation.

Immediate:

Sit upright, O₂ to maintain SpO₂ > 92%. BiPAP if respiratory distress.
Furosemide (Lasix) 80mg IV push (give 2× their home oral dose as IV dose -she takes 40mg PO daily → give 80mg IV; can escalate to 100mg / 2.5× if prior dose was inadequate). Can redose in 2h if < 100mL UOP.
If inadequate response: double the dose → 160mg IV. If still inadequate → add metolazone (Zaroxolyn) 5mg PO 30 min before next lasix dose (sequential nephron blockade).

Monitoring: Strict I&Os, daily weights (goal: net negative 1–2L/day), BMP BID (watch K⁺ and Cr -"creatinine bumps" of 0.3–0.5 are acceptable if patient is decongesting).

Home GDMT: Continue metoprolol succinate (Toprol XL) at current dose (do NOT uptitrate during decompensation, but do NOT stop unless cardiogenic shock). Hold ACEi/ARNI if hypotensive or Cr rising sharply.

Discharge when: Stable on oral diuretics × 24h, ambulatory SpO₂ > 92%, weight at or near dry weight, scheduled HF clinic follow-up within 7 days.

Monitoring Parameters -Acute Decompensated Heart Failure

Parameter	Frequency	Target / Action
Daily weights	Every morning, same scale, before breakfast	Target 1-2 kg/day net loss during active diuresis. Weight gain > 2 lbs/day = fluid retention → uptitrate diuretics.
Strict I&Os	Every shift (q8h tallies)	Net negative 1-2 L/day during active diuresis. UOP ≥ 0.5 mL/kg/hr. If UOP drops, consider diuretic dose increase or combination diuretic therapy.
BMP (K⁺, Cr, Na⁺)	Daily while on IV diuretics; q1-2 days after RAAS inhibitor initiation or titration	K⁺ 4.0-5.0 (RAAS inhibitors raise K⁺, diuretics lower it). Cr rise ≤ 0.3 acceptable with diuresis. Na < 130 → consider fluid restriction.
Blood pressure	q4-6h inpatient; each clinic visit outpatient	SBP ≥ 90 for ARNI/ACEi/ARB titration. Tolerate asymptomatic SBP 90-100 if on GDMT. Hold vasodilators if symptomatic hypotension.
Heart rate	q4-6h inpatient; each visit outpatient	Resting HR 60-70 on maximally tolerated beta-blocker. Do NOT uptitrate BB during active decompensation.
BNP / NT-proBNP	Admission and pre-discharge (trend)	> 30% reduction from admission = adequate decongestion. Discharge BNP predicts readmission risk.
Echocardiogram (EF)	Reassess at 3-6 months after GDMT optimization	EF improvement on GDMT may reclassify HFrEF → HFimpEF. Continue all GDMT even if EF improves.
Telemetry	Continuous during IV diuresis and inotrope use	Monitor for AF, VT, bradycardia from BB/digoxin. Discontinue when stable on oral regimen.
Functional status	Each assessment	Dyspnea improvement, orthopnea resolution, exercise tolerance, appetite. The exam matters more than the labs.

Before discharge: Stable on oral diuretics ≥ 24h, weight trending down or at dry weight, BMP stable, GDMT initiated or uptitrated, follow-up within 7 days, patient weighed and educated on daily weights and 2g Na restriction.

Test	Rationale	Key Values
BNP / NT-proBNP	Diagnosis and prognostication. Trend to assess treatment response.	BNP >400 pg/mL or NT-proBNP >900 pg/mL (age <75) supports HF. Obesity falsely lowers BNP.
TTE (echocardiogram)	Classify HFrEF (EF ≤40%) vs HFpEF (EF ≥50%). Assess wall motion, valves, diastolic function, RVSP.	EF ≤40% = HFrEF. EF 41–49% = HFmrEF. LA dilation, elevated E/e′ suggest elevated filling pressures.
BMP	Cr (cardiorenal syndrome), K⁺ (before RAAS inhibitors), Na⁺ (hyponatremia = poor prognosis), bicarb	Cr rise >0.3 from baseline = cardiorenal. Na <135 = independent mortality predictor.
CBC	Anemia worsens HF (high-output physiology). Infection as precipitant.	Hgb <10 → evaluate and treat anemia. Leukocytosis → infectious trigger?
Iron studies	Iron deficiency (even without anemia) worsens HF outcomes. IV iron improves symptoms.	Ferritin <100 OR ferritin 100–299 + TSAT <20% = iron deficient. Treat with IV iron FAIR-HF, 2009.
TSH	Hyper- and hypothyroidism are reversible causes of HF.	Check in all new HF diagnoses.
ECG	Ischemia, arrhythmia (new AF), LVH, LBBB (CRT candidacy if QRS ≥150 ms).	LBBB + EF ≤35% + QRS ≥150 ms → strong CRT indication.
Troponin	Rule out ACS as trigger for decompensation. Chronic mild elevation common in HF.	Acute rise-and-fall → ACS workup. Chronic low-level elevation = myocardial stress (not necessarily ACS).
CXR	Pulmonary edema (cephalization, Kerley B lines, effusions), cardiomegaly.	~20% of ADHF patients have a normal CXR. Do not rely on CXR alone to rule out HF.